The success of clinical trials focused on multi-modal treatment (ICIs with VEGF inhibitors or CAR-T cells/TIL that target multiple tumor antigens) has demonstrated that identification of patient subsets will be a key strategy moving forward in the treatment of HCC and BTC. The gene discussed is VEGFA; the disease is neoplasm.